Overview of diseases
Our initial focus is on severe inherited retinal diseases for which there are no currently approved or satisfactory treatments. Our goal is to provide patients with long-lasting treatment that leverages our cutting-edge expertise in combining a gene therapy-based approach with our proprietary technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics. Our two lead product candidates are being developed to treat two sight-threatening rare diseases: Leber Hereditary Optic Neuropathy (LHON) and Retinitis Pigmentosa (RP). In the future, we anticipate investigating the ability of one candidate to treat Geographic Atrophy in Dry-AMD.
Leber Hereditary Optic Neuropathy (LHON)
LHON is caused by defects in mitochondrial genes encoding for proteins called NADH dehydrogenase. 95% of LHON cases are due to mutations in the mitochondrial genes ND1, ND4 and ND6, which encode proteins of the respiratory chain Complex I, an important component of energy production within the mitochondrion and therefore the cell. The ND4 mutation is responsible for the majority of LHON cases, representing around 70% in Europe and North America and 80 to 85% in Asia.
Although the genetic defect is present throughout the body, LHON symptoms are almost uniquely limited to retinal ganglion cells, or RGCs, located on the surface of the retina. These cells receive visual information from photoreceptors and transmit it to the brain. However, genetic mutation in the mitochondrial genes ND1, ND4 and ND6 disrupt Complex I, starving the RGCs of energy and making them no longer able to transmit signals to the brain. The patient turns blind.
Onset of vision loss due to LHON typically occurs between 15 and 35 years of age. Vision loss often occurs in a sequential fashion where one eye is affected first, followed by the second eye on average two months later.
The dramatic loss of vision experienced by LHON patients is life-changing and affects patients and their families socially, emotionally, and financially. LHON severely curtails patients’ ability to perform day-to-day activities, significantly reduces their autonomy, and alters their life choices.
Retinitis Pigmentosa (RP)
Retinitis Pigmentosa (RP) is the leading cause of hereditary blindness in developed countries, with a prevalence of about 1.5 million people throughout the world. In Europe and the United States, about 350,000 to 400,000 patients suffer from RP, and every year between 15,000 and 20,000 new patients become affected by vision loss due to RP. There is currently no cure for RP, and it is considered a rare and orphan disease in the United States and Europe.
RP actually represents a group of related genetic eye disorders that clinically manifest in both non-syndromic forms involving isolated visual disability, as well as syndromic forms involving other organs or tissues (such as Usher Disease or Bardet-Biedl syndrome, which manifests both in the retina and in the cochlea of the ear). The mutations that cause RP are heterogeneous and include recessive, dominant, and X-linked forms of more than 60 genes affecting a variety of cell functions. Syndromic forms of RP are equally heterogeneous.
RP is characterized by progressive vision loss. Initially, rod photoreceptors degenerate, causing the loss of peripheral vision. This is then followed by degeneration of cone photoreceptors, which results in the loss of central vision. The first symptom of RP is usually difficulty with night vision, which can occur as early as childhood. The disease progresses over a period of years or even decades, and ultimately leads to blindness. Some patients become blind as early as age 30; the majority of patients become legally blind before the age of 60.
The following image illustrates the deterioration of normal vision to blindness in RP:
Geographic Atrophy in Dry-AMD
Although Retinitis Pigmentosa (RP) and Age-Related Macular Degeneration (AMD) have very different origins, both diseases are characterized by degeneration of the photoreceptor cells of the retina. There is currently no cure for either condition.
AMD is a degenerative disorder driven by genetic and environmental factors. The disease specifically affects the macula, i.e. the central retina, sparing the peripheral retina. Thus, peripheral visual field is usually preserved even in the late stages of the disease. But while the retention of peripheral vision allows the patient to maintain some degree of autonomy, the loss of central vision has a significant impact on day-to-day activities such as reading, facial recognition and tasks requiring attention to intricate details.
Macular degeneration typically occurs in patients over 55. The early form of AMD is called dry-AMD and can evolve over time to late AMD. Late AMD can take two forms, either wet-AMD or Geographic Atrophy (GA). Approximately 15 million people are affected with AMD in the United States, with a global prevalence of 170 million. Late-stage AMD patients represent only a fraction of this population, and in turn a fraction of these are patients suffering from GA. The effect of age on GA is significant, as its prevalence increases significantly in those older than 75, reaching 22% in the population over 90
Clinical development summary
Our pipeline currently consists of:
- Two lead product candidates for the treatment of sight-threatening retinal degenerative diseases, together with
- Products in preclinical development targeting ophthalmic and neurodegenerative diseases
Visit www.clinicaltrials.gov and search for “GenSight Biologics” to learn more about our ongoing clinical trials listed below.
GS010: Phase 3 gene therapy product candidate for treatment of treatment of LHON due to ND4 mutation
- Phase I/II: Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients
- RESCUE: Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months from Onset in LHON Due to the ND4 Mutation
- REVERSE: Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year from Onset in LHON Due to the ND4 Mutation
- REFLECT: Efficacy and Safety Study of Bilateral Intravitreal Injection of GS010 for the Treatment of Vision Loss up to 1 Year from Onset in LHON Due to the ND4 Mutation
- REALITY: LHON Registry Study to Understand the Evolution of Visual Functional and Structural Changes and Other Associated Symptoms in Patients with LHON
- RESCUE and REVERSE Long-term Follow-up (RESCUE/REVERSE)
GS030: gene therapy product candidate based on Optogenetics to treat Retinitis Pigmentosa
- PIONEER: Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa